Type 2 Diabetes Mellitus, Chronic Kidney Disease - Kansas City MO

Summary:

Phase 2 - A parallel-group treatment, double-blind, three-arm study to assess
efficacy and safety of finerenone plus empagliflozin compared with either
finerenone or empagliflozin in participants with Chronic Kidney Disease (CKD)
and Type 2 Diabetes.

Inclusion:
 Type 2 Diabetes (T2D)
 Chronic Kidney Disease
 GFR > 30
 UACR > 300

Exclusion:
 Type 1 Diabetes (T1D)
 Chronic Kidney Disease not on dialysis.
 Renal allograft in place or a scheduled kidney transplant.

This is not a complete list of inclusion and exclusion criteria for this study.

Qualified Participants May Receive:

Qualified Participants of this study will receive:

• Study drug(s)
• Tests
• Examinations
• Medical care 
• $75.00 per completed clinic visit.
• $250.00 for Visit 1 if you remain at the site for 4-6 hours for blood pressure monitoring and participate in ambulatory blood pressure monitoring